Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway

[1]  B. Monia,et al.  PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells , 2002, Oncogene.

[2]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[3]  J. Gera,et al.  Signal Pathways Involved in Activation of p70S6K and Phosphorylation of 4E-BP1 following Exposure of Multiple Myeloma Tumor Cells to Interleukin-6* , 2002, The Journal of Biological Chemistry.

[4]  T. Franke,et al.  Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses , 2002, Oncogene.

[5]  John Calvin Reed,et al.  The AKT kinase is activated in multiple myeloma tumor cells. , 2001, Blood.

[6]  J. Woodgett,et al.  PKB/AKT: functional insights from genetic models , 2001, Nature Reviews Molecular Cell Biology.

[7]  D. Chauhan,et al.  Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma , 2001, Oncogene.

[8]  R. Kyle,et al.  Update on the treatment of multiple myeloma. , 2001, The oncologist.

[9]  R. Parsons,et al.  PTEN: life as a tumor suppressor. , 2001, Experimental cell research.

[10]  S. Rudikoff,et al.  Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo , 2000, Oncogene.

[11]  D. Jelinek,et al.  Mechanisms of myeloma cell growth control. , 1999, Hematology/oncology clinics of North America.

[12]  E. Kandel,et al.  The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. , 1999, Experimental cell research.

[13]  T. Franke,et al.  Protein kinase C-α overexpression stimulates Akt activity and suppresses apoptosis induced by interleukin 3 withdrawal , 1999, Oncogene.

[14]  B. Barlogie,et al.  Recent advances in the treatment of multiple myeloma. , 1999, Current opinion in hematology.

[15]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[16]  L. Flechner,et al.  Protein Kinase C-δ Is an Important Signaling Molecule in Insulin-Like Growth Factor I Receptor-Mediated Cell Transformation , 1998, Molecular and Cellular Biology.

[17]  A. Cuadrado,et al.  Activation of Akt/Protein Kinase B by G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[18]  F. Hobbs,et al.  Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.

[19]  Tomohiko Maehama,et al.  The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.

[20]  A. Toker,et al.  Signalling through the lipid products of phosphoinositide-3-OH kinase , 1997, Nature.

[21]  Y. Shima,et al.  Myeloma biology and therapy. Present status and future developments. , 1997, Hematology/oncology clinics of North America.

[22]  G. Tricot,et al.  Cytogenetics and molecular genetics in multiple myeloma. , 1997, Hematology/oncology clinics of North America.

[23]  P. Cohen,et al.  Mechanism of activation of protein kinase B by insulin and IGF‐1. , 1996, The EMBO journal.

[24]  A. Arcaro,et al.  Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. , 1993, The Biochemical journal.

[25]  D. Siegel,et al.  Biology and treatment of multiple myeloma. , 1993, Blood reviews.